Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Solid Neoplasm: early-phase trial registry
2 of 13 indexed Solid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 2 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Solid Neoplasm: 13 US clinical trials tracked, 2 recruiting.
Solid Neoplasm is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition solid-neoplasm
OPEN 2 | RECR 15% | LATE 0 | EARLY 10 | RANK #1315 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Arthroplasty, Replacement, Knee (15% recruiting · 13 trials)
Solid Neoplasm lists 2 open slots (15% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Solid Neoplasm is recruiting below its size-band peers.
2 of 13 indexed trials (15.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Solid Neoplasm research.
National Cancer Institute (NCI) accounts for 5 of 13 trials (38.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Solid Neoplasm trials plan to enrol fewer than 100 people.
Median target enrolment is 41 among the 13 trials that report a genuine target (sentinel values excluded). 10 of those (76.9%) plan for fewer than 100 participants.
-
Solid Neoplasm research is mostly interventional.
12 interventional and 1 observational studies make up this index (92.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
UWCCC Molecular Tumor Board Registry
University of Wisconsin, Madison
NCT03023202
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
NCT03604315
Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer
City of Hope Medical Center
NCT02517034
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
NCT00740805
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
NCT02713269
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT01552356
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Children's Oncology Group
NCT03834961
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
NCT04147494
Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy
University of Southern California
NCT03098277
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
NCT02188264
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
National Cancer Institute (NCI)
NCT01538095
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
NCT00085553
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
University of Chicago
NCT02540876
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Solid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Solid Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Solid Neoplasm page
13 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Solid Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Solid Neoplasm trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Neoplasm condition card totals 13 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.